Literature DB >> 15296678

Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS).

Jolanda De Vries1, Helen Michielsen, Guus L Van Heck, Marjolein Drent.   

Abstract

Fatigue is a major problem in a wide range of diseases including sarcoidosis. However, there is no standard measure for assessing fatigue. Therefore, the aim of the present study was to evaluate the usefulness of the Fatigue Assessment Scale (FAS) in two samples of sarcoidosis patients. Sample 1 included 1 046 members of the Dutch Sarcoidosis Society and Sample 2 consisted of 80 sarcoidosis patients of the outpatient clinic of the Sarcoidosis Management Centre Maastricht, the Netherlands. All patients completed the FAS as well as the 'energy and fatigue' subscale of the WHOQOL-100. Additionally, the participants of Sample 1 filled in the Beck Depression Inventory (BDI). In addition, 241 patients of Sample 1 completed the FAS for the second time after a one-week interval. The FAS appeared to be a unidimensional scale. The content validity, construct validity and internal consistency of the FAS were good. The test - retest reliability was.89. Four FAS items appeared to have a gender bias: three items were uniformly biased and one item non-uniformly biased. Correction for gender bias in the calculation of the FAS total score is not indicated. In conclusion, the FAS is a promising measure for assessing fatigue in sarcoidosis patients.

Entities:  

Mesh:

Year:  2004        PMID: 15296678     DOI: 10.1348/1359107041557048

Source DB:  PubMed          Journal:  Br J Health Psychol        ISSN: 1359-107X


  74 in total

Review 1.  Patient reported outcome measures (PROMs) in sarcoidosis.

Authors:  Rikke Flor Thunold; Anders Løkke; Adam Langballe Cohen; Hilberg Ole; Elisabeth Bendstrup
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

2.  Comparison of symptom clusters associated with fatigue in older and younger survivors of colorectal cancer.

Authors:  S C Agasi-Idenburg; M S Y Thong; C J A Punt; M M Stuiver; N K Aaronson
Journal:  Support Care Cancer       Date:  2016-10-21       Impact factor: 3.603

3.  A composite score to assess treatment response in pulmonary sarcoidosis: the Sarcoidosis Treatment Score (STS).

Authors:  Robert P Baughman; Michael Tillinger; Yimin Qin; Nadera Sweiss; Elyse E Lower
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

4.  Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.

Authors:  Lara Heij; Marieke Niesters; Maarten Swartjes; Elske Hoitsma; Marjolein Drent; Ann Dunne; Jan C Grutters; Oscar Vogels; Michael Brines; Anthony Cerami; Albert Dahan
Journal:  Mol Med       Date:  2012-11-15       Impact factor: 6.354

Review 5.  The Clinical Features of Sarcoidosis: A Comprehensive Review.

Authors:  Marc A Judson
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

6.  Measuring activity in patients with sarcoidosis - a pilot trial of two wrist-worn accelerometer devices.

Authors:  Christopher P Atkins; Andy P Jones; Andrew M Wilson
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

7.  Development and testing of item response theory-based item banks and short forms for eye, skin and lung problems in sarcoidosis.

Authors:  David E Victorson; Seung Choi; Marc A Judson; David Cella
Journal:  Qual Life Res       Date:  2013-11-09       Impact factor: 4.147

8.  Fatigue in the general population: German normative values of the EORTC QLQ-FA12.

Authors:  Andreas Hinz; Joachim Weis; Elmar Brähler; Anja Mehnert
Journal:  Qual Life Res       Date:  2018-06-16       Impact factor: 4.147

9.  Personality and fatigue in patients with benign or malignant breast disease.

Authors:  Helen J Michielsen; Alida F W Van der Steeg; Jan A Roukema; Jolanda De Vries
Journal:  Support Care Cancer       Date:  2007-02-07       Impact factor: 3.603

10.  Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial.

Authors:  Elyse E Lower; Atul Malhotra; Victoria Surdulescu; Robert P Baughman
Journal:  J Pain Symptom Manage       Date:  2012-08-20       Impact factor: 3.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.